Rxo (RXO) Operating Expenses (2021 - 2026)

Rxo (RXO) has reported Operating Expenses for 6 consecutive years, with $218.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses changed 0.46% year-over-year to $218.0 million; the trailing twelve-month figure through Jun 2026 stood at $851.0 million (up 2.78% YoY), and the FY2025 full-year result was $870.0 million, up 24.46% from the prior year.
• Operating Expenses improved to $218.0 million in Q2 2026 per RXO's latest filing, from $204.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $236.0 million in Q4 2024 and bottomed at $145.0 million in Q2 2023.
• Historically, Operating Expenses has averaged $180.6 million across 5 years, with a median of $162.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses retreated 14.2% in 2023, then surged 57.33% in 2024.
• Over 5 years, Operating Expenses stood at $159.0 million in 2022, then retreated by 5.66% to $150.0 million in 2023, then soared by 57.33% to $236.0 million in 2024, then dropped by 8.05% to $217.0 million in 2025, then increased by 0.46% to $218.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $218.0 million, $204.0 million, and $217.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.